- Published on
Theophylline poisoning is a potentially life-threatening toxicologic emergency resulting from excessive levels of a methylxanthine drug commonly used for respiratory conditions. Its toxicity is primarily due to increased endogenous catecholamine release, antagonism of adenosine receptors, and inhibition of phosphodiesterase at high concentrations. These mechanisms lead to widespread stimulation of the cardiovascular and central nervous systems. Theophylline is available in both immediate-release and sustained-release formulations, with peak absorption occurring within 1–2 hours for immediate-release and up to 6–10 hours for sustained-release forms, which can delay toxicity.
Toxicity can occur in several patterns. Acute overdose refers to a large ingestion in a patient without prior exposure, whereas acute-on-chronic toxicity occurs when a patient already on therapy takes an excessive dose. Chronic toxicity develops gradually due to accumulation, often from drug interactions, organ dysfunction such as liver disease or heart failure, or repeated dosing errors. Importantly, chronic toxicity tends to cause severe symptoms at lower serum levels compared to acute overdose.
Clinically, theophylline poisoning affects multiple organ systems. Cardiovascular manifestations include sinus tachycardia, atrial and ventricular dysrhythmias, and in severe cases ventricular tachycardia due to β1 stimulation and adenosine antagonism. Hypotension may occur at very high levels due to β2-mediated vasodilation and can be resistant to standard treatments. Neurologically, patients may present with tremors, agitation, altered mental status, and seizures, which are a hallmark of severe toxicity and occur more frequently in chronic intoxication. Gastrointestinal symptoms are common, particularly persistent nausea and vomiting, which can be severe and refractory.
Metabolic abnormalities are also prominent, including hypokalemia due to intracellular potassium shift, hyperglycemia, leukocytosis, and metabolic acidosis with elevated lactate. Hypophosphatemia and hypomagnesemia may also occur. Sustained-release formulations may form pharmacobezoars in the gastrointestinal tract, delaying absorption and prolonging toxicity.
Diagnosis is confirmed by measuring serum theophylline levels, with concentrations ≥20 μg/mL considered toxic. Serial levels are essential to ensure that peak levels have been reached, especially with sustained-release products. Electrocardiographic monitoring is critical due to the high risk of dysrhythmias. Additional laboratory testing helps assess complications such as electrolyte disturbances and metabolic derangements.
Management begins with stabilization of airway, breathing, and circulation, along with cardiac monitoring. Intravenous fluids are administered for hypotension, and rate control for supraventricular tachyarrhythmias may require β-blockers or calcium channel blockers. Notably, adenosine is often ineffective because its action is antagonized by theophylline. Ventricular dysrhythmias are treated according to standard protocols. Seizures should be treated aggressively with benzodiazepines, as other agents such as phenytoin are ineffective and may worsen outcomes.
Gastrointestinal decontamination plays a major role in treatment. Activated charcoal is highly effective, particularly when given in multiple doses, as it enhances elimination by interrupting enterohepatic circulation. Whole-bowel irrigation may be used for sustained-release ingestions to remove unabsorbed drug. Antiemetics such as metoclopramide or ondansetron may be required for severe vomiting. Electrolyte abnormalities should be corrected cautiously, especially hypokalemia, to avoid rebound hyperkalemia as drug levels fall.
In severe cases, extracorporeal removal such as hemodialysis or hemoperfusion is indicated, particularly in patients with very high serum levels, refractory seizures, or significant dysrhythmias. These methods are highly effective due to theophylline’s pharmacokinetic properties.
Patients with severe toxicity, high serum levels, or complications such as seizures or refractory hypotension require intensive care admission. Those with mild symptoms may be discharged once serum levels are clearly decreasing and below toxic thresholds, provided they remain clinically stable. Close follow-up is necessary, especially in patients on chronic therapy, to adjust dosing and prevent recurrence.
A key point in theophylline poisoning is that seizures and tachydysrhythmias are major causes of morbidity and mortality, and early recognition with aggressive treatment significantly improves outcomes. Multi-dose activated charcoal remains one of the most effective interventions in enhancing drug elimination.
Toxicity can occur in several patterns. Acute overdose refers to a large ingestion in a patient without prior exposure, whereas acute-on-chronic toxicity occurs when a patient already on therapy takes an excessive dose. Chronic toxicity develops gradually due to accumulation, often from drug interactions, organ dysfunction such as liver disease or heart failure, or repeated dosing errors. Importantly, chronic toxicity tends to cause severe symptoms at lower serum levels compared to acute overdose.
Clinically, theophylline poisoning affects multiple organ systems. Cardiovascular manifestations include sinus tachycardia, atrial and ventricular dysrhythmias, and in severe cases ventricular tachycardia due to β1 stimulation and adenosine antagonism. Hypotension may occur at very high levels due to β2-mediated vasodilation and can be resistant to standard treatments. Neurologically, patients may present with tremors, agitation, altered mental status, and seizures, which are a hallmark of severe toxicity and occur more frequently in chronic intoxication. Gastrointestinal symptoms are common, particularly persistent nausea and vomiting, which can be severe and refractory.
Metabolic abnormalities are also prominent, including hypokalemia due to intracellular potassium shift, hyperglycemia, leukocytosis, and metabolic acidosis with elevated lactate. Hypophosphatemia and hypomagnesemia may also occur. Sustained-release formulations may form pharmacobezoars in the gastrointestinal tract, delaying absorption and prolonging toxicity.
Diagnosis is confirmed by measuring serum theophylline levels, with concentrations ≥20 μg/mL considered toxic. Serial levels are essential to ensure that peak levels have been reached, especially with sustained-release products. Electrocardiographic monitoring is critical due to the high risk of dysrhythmias. Additional laboratory testing helps assess complications such as electrolyte disturbances and metabolic derangements.
Management begins with stabilization of airway, breathing, and circulation, along with cardiac monitoring. Intravenous fluids are administered for hypotension, and rate control for supraventricular tachyarrhythmias may require β-blockers or calcium channel blockers. Notably, adenosine is often ineffective because its action is antagonized by theophylline. Ventricular dysrhythmias are treated according to standard protocols. Seizures should be treated aggressively with benzodiazepines, as other agents such as phenytoin are ineffective and may worsen outcomes.
Gastrointestinal decontamination plays a major role in treatment. Activated charcoal is highly effective, particularly when given in multiple doses, as it enhances elimination by interrupting enterohepatic circulation. Whole-bowel irrigation may be used for sustained-release ingestions to remove unabsorbed drug. Antiemetics such as metoclopramide or ondansetron may be required for severe vomiting. Electrolyte abnormalities should be corrected cautiously, especially hypokalemia, to avoid rebound hyperkalemia as drug levels fall.
In severe cases, extracorporeal removal such as hemodialysis or hemoperfusion is indicated, particularly in patients with very high serum levels, refractory seizures, or significant dysrhythmias. These methods are highly effective due to theophylline’s pharmacokinetic properties.
Patients with severe toxicity, high serum levels, or complications such as seizures or refractory hypotension require intensive care admission. Those with mild symptoms may be discharged once serum levels are clearly decreasing and below toxic thresholds, provided they remain clinically stable. Close follow-up is necessary, especially in patients on chronic therapy, to adjust dosing and prevent recurrence.
A key point in theophylline poisoning is that seizures and tachydysrhythmias are major causes of morbidity and mortality, and early recognition with aggressive treatment significantly improves outcomes. Multi-dose activated charcoal remains one of the most effective interventions in enhancing drug elimination.
0 Comments
